Trevena appoints Anne Phillips to board
This article was originally published in Scrip
Trevena, a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, has named Dr Anne M Phillips to its board of directors. Dr Phillips replaces Farah Champsi, managing director at Alta Partners, who is stepping down from the board following the company's initial public offering earlier this year. Dr Phillips is currently senior vice-president of clinical, medical and regulatory affairs at Novo Nordisk.